Neurocrine Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEUROCRINE, and what generic alternatives to NEUROCRINE drugs are available?
NEUROCRINE has two approved drugs.
There are twenty-two US patents protecting NEUROCRINE drugs.
There are one hundred and ninety-five patent family members on NEUROCRINE drugs in thirty-four countries.
Summary for Neurocrine
| International Patents: | 195 |
| US Patents: | 22 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Neurocrine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | AB | RX | Yes | No | 11,026,931 | ⤷ Sign Up | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | AB | RX | Yes | No | 10,940,141 | ⤷ Sign Up | ⤷ Sign Up | |||
| Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE;ORAL | 218390-001 | Apr 30, 2024 | RX | Yes | No | 10,952,997 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
